Bronconex Acticap

Država: Nova Zelandija

Jezik: angleščina

Source: Medsafe (Medicines Safety Authority)

Aktivna sestavina:

Mometasone furoate 400ug (anhydrous)

Dostopno od:

Organon (New Zealand) Limited

INN (mednarodno ime):

Mometasone furoate 400 µg (anhydrous)

Odmerek:

400 mcg/dose

Farmacevtska oblika:

Powder for inhalation

Sestava:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Enote v paketu:

Inhaler, metered, DPI, (sample), 14 dose units

Razred:

Prescription

Tip zastaranja:

Prescription

Izdeluje:

MSD International GmbH (Singapore Branch)

Terapevtske indikacije:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Povzetek izdelek:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Datum dovoljenje:

2000-12-05